ACE2 News and Research

RSS

D614G mutation in SARS-CoV-2 increases viral fitness and infectivity

Researchers from the Duke Human Vaccine Institute and Duke University, Durham NC, USA, recently analyzed the D614G mutation in SARS-CoV-2 in the context of a soluble S ectodomain construct. Their study has been published in the preprint server bioRxiv.

14 Oct 2020

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Researchers at The Medical Research Council Laboratory of Molecular Biology have conducted a study showing how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein interacts with host cell factors in ways that promote the formation of syncytia.

13 Oct 2020

Scientists explain why some COVID-19 patients develop neurological symptoms

Now, a new study published on the preprint server bioRxiv sheds light on the mechanism behind brain involvement in the COVID-19 pandemic. A team of researchers at the Krembil Research Institute and the University of Toronto in Canada aimed to understand further the potential mechanisms underlying SARS-CoV-2 tropism for brain vasculature to see how infection occurs in the brain.

13 Oct 2020

Why blood type O might lower risk for SARS-CoV-2 infection

The author hypothesizes that people with non-O blood groups may have highest contact with the SARS-CoV-2 virus via the formation of in intermediate structure, resulting in possibly higher infection rates and more severe symptoms.

12 Oct 2020

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

A new study by Uppsala University researchers published on the preprint server bioRxiv in October 2020 shows possible links between the angiotensin-converting enzyme 2 (ACE2) host cell receptors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the entry of viral particles into the cell via endocytosis and autophagy.

12 Oct 2020

COVID-19 survivors may have protective antibodies for 4 months

The study, published in the journal Science Immunology, highlights the body's immune response against COVID-19. Also, it offers hope that people who are infected with the SARS-CoV-2 virus will develop lasting protection against reinfection.

11 Oct 2020

Elevated plasma ACE2 activity persists months after SARS-CoV-2 infection

Recently, researchers from the University of Melbourne and Immune Therapies Group, Burnet Institute, Melbourne, reported that downregulation of cardiac ACE2 is linked to increased plasma ACE2 activity. This study is summarized in a preprint paper published in medRxiv.

11 Oct 2020

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Researchers have recovered and identified the various types of neutralizing antibodies for SARS-CoV-2 from convalescent COVID-19 patients. Of these, they identified three that are extremely potent and could be used to develop treatment therapies.

11 Oct 2020

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

The emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation D614G has raised many questions, including whether it will cause the virus to become resistant to the vaccines produced against earlier versions of the virus. A new study published in the journal npj Vaccines in October 2020 shows that this may be an unfounded fear.

11 Oct 2020

Analysis of existing comorbidities and COVID-19 mortality

As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.

11 Oct 2020

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Researchers identify a promising method to stop COVID-19 infection

While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.

8 Oct 2020

Study: New viral mutations would not impact the efficacy of Covid-19 vaccine candidates

Vaccines currently being developed for Covid-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologist.

8 Oct 2020

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.

8 Oct 2020

SARS-CoV-2 spike protein may induce analgesia

A recent study published in the journal Pain in October 2020 adds another piece to the puzzle, showing that the virus is capable of dulling pain pathways. This may contribute to its early and extensive spread.

7 Oct 2020

New clinical report on brain changes in deceased COVID-19 patients

German researchers published a report on a series of cases on post mortem findings of COVID-19 patients who succumbed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection along with neurological complications. Their study titled “Neuropathology of patients with COVID-19 in Germany: a post-mortem case series” is published in the latest issue of The Lancet Neurology.

6 Oct 2020

Using virus-like particles to study SARS-CoV-2 assembly, budding, and entry

In a recent preprint paper published on the bioRxiv server, researchers from the Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, IN, discuss their efforts to assess the 4 SARS-CoV-2 structural proteins for their ability to produce VLPs from human cells to create a competent system for BSL-2 studies of SARS-CoV-2.

6 Oct 2020

Plasma ACE2 concentration associated with increased risk of major cardiovascular events

A team of scientists at the Population Health Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, in Ontario, Canada, revealed that increased plasma ACE2 levels in the blood could indicate a higher risk of major cardiovascular events. The study is published in the journal The Lancet.

6 Oct 2020

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

A recent paper published in the preprint server medRxiv in September 2020 discusses the “clinically relevant variation in the expression of COVID-19-related genes”, which is associated with the host and environmental factors, as well as host genetic factors.

6 Oct 2020

Cats and dogs are low risk for SARS-CoV-2 transmission to humans

Researchers from the College of Veterinary Medicine and Biomedical Sciences, Colorado State University studied the possible transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among domestic cats and dogs.

5 Oct 2020